The combination of HDL-C elevation, lowering of triglycerides and further LDL-C reduction
accomplished by the addition of niacin to statin medication would improve endothelial
function as compared to LDL-C reduction alone in patients with and without coronary artery
disease and the combination of low HDL-C/high triglycerides.
The combination of lipid lowering therapy would have beneficial effects on markers of
inflammation. These benefits would be particularly evident in women.